Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson’s Disease

Author(s): Andrew Schneider, Adam T. Sari, Hasan Alhaddad, Youssef Sari*

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 19 , Issue 3 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Parkinson’s Disease (PD) is a neurodegenerative disease involving degeneration of dopaminergic neurons of the nigrostriatal pathways. Over the past decades, most of the medications for the treatment of PD patients have been used to modulate dopamine concentrations in the basal ganglia. This includes levodopa and its inhibitory metabolizing enzymes. In addition to modulating dopamine concentrations in the brain, there are D2-like dopamine receptor agonists that mimic the action of dopamine to compensate for the deficit in dopamine found in PD patients. Muscarinic antagonists’ drugs are used rarely due to some side effects. Monoamine oxidase inhibitors are among the first in line, and are considered popular drugs that reduce the metabolism of dopamine in PD patients. Furthermore, we discussed in this review the existence of certain glutamate receptor antagonists for the treatment of PD. Alternatively, we further discussed the potential therapeutic role of adenosine (2A) receptor antagonists, such as tozadenant and istradefylline in the treatment of PD. We also discussed the important role of serotonin1A receptor agonist, adrenergic autoreceptors (α2) antagonists and calcium channel blockers in the treatment of PD. Finally, neurotrophic factors, such as glial cell line-derived neurotrophic growth factor and brain-derived neurotrophic factor are considered the primary factors for neuroprotection in PD.

Keywords: Dopamine, MAO-B, glutamate, BDNF, GDNF, Parkinson's Disease (PD).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 17 August, 2020
Page: [195 - 206]
Pages: 12
DOI: 10.2174/1871527319666200525011110
Price: $65

Article Metrics

PDF: 47